Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 86 Days Sales Outstanding is 30.56 as of Jun. 2026, which is 33% below its 10-year median of 45.68. GuruFocus rates SARTF with a GF Score™ of 86/100 and a GF Value™ of $231.78 (Fairly Valued). The stock has 6 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Sartorius AG ranks better than 92.36% on this metric.
Sartorius AG's average Accounts Receivable for the
three
months ended in Jun. 2026 was $352 Mil. Sartorius AG's Revenue for the
three
months ended in Jun. 2026 was $1,050 Mil.
Hence, Sartorius AG's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 30.56.
The historical rank and industry rank for Sartorius AG's Days Sales Outstanding or its related term are showing as below:
SARTF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 27 Med: 45.68 Max: 68.01
Current: 29.07
During the past 13 years, Sartorius AG's highest Days Sales Outstanding was 68.01. The lowest was 27.00. And the median was 45.68.
SARTF's Days Sales Outstanding is ranked better than 92.36% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs SARTF: 29.07
Sartorius AG's Days Sales Outstanding
declined
from Jun. 2025 (31.77) to Jun. 2026 (30.56).
Sartorius AG (OTCPK:SARTF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Sartorius AG Days Sales Outstanding Related Terms
Sartorius AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a Days Sales Outstanding of 30.56 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sartorius AG and its competitors. This is 33% below median its historical median of 45.68. Over the past decade, Sartorius AG's Days Sales Outstanding has ranged from 27.00 to 68.01. According to the industry distribution chart, Sartorius AG ranks #62 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 7.6%.
Is Sartorius AG's Days Sales Outstanding too high?
Sartorius AG's current Days Sales Outstanding of 30.56 is 33% below median its 10-year median of 45.68. Over the past 10 years, this metric has ranged from a low of 27.00 to a high of 68.01. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. Sartorius AG's value of 30.56 is 53.1% below this industry median. Based on the distribution chart, Sartorius AG ranks #62 out of 812 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius AG has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #62 out of 812 companies for Days Sales Outstanding. This places Sartorius AG in the top 8% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 65.17. Sartorius AG's value of 30.56 is 53.1% below this benchmark. Historically, Sartorius AG's own Days Sales Outstanding has ranged from 27.00 to 68.01 over the past decade. While the company's 10-year median is 45.68 vs. the industry median of 65.17, Sartorius AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Days Sales Outstanding of 30.56 is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Days Sales Outstanding is 30.56, which is 33% below median its own 10-year median of 45.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Fairly Valued. The stock's GF Value™ is $231.78, compared to a current price of $212.80 — trading 8.2% below its estimated fair value. The current Days Sales Outstanding is 30.56, which is 33% below median its 10-year median of 45.68 and 53.1% below the Medical Devices & Instruments industry median of 65.17. Sartorius AG's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Days Sales Outstanding is 30.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 8.2% below its estimated GF Value™ of $231.78.
GuruFocus considers Sartorius AG to be Fairly Valued.
Key valuation signals for SARTF:
Days Sales Outstanding: 30.56 (33% below median its 10-year median of 45.68)
GF Value™: $231.78 vs. price of $212.80 (8.2% below fair value)
Industry Position: 53.1% below the Medical Devices & Instruments median (#62 of 812)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
86GF Score
Get the complete analysis for SARTF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
